Schizophrenia patients with cannabis history showed better cognitive performance and more brain activity than non-users

In an fMRI study, first-episode schizophrenia patients with a cannabis history performed better on cognitive control tasks and showed higher prefrontal cortex activation than patients without cannabis history, though both groups performed worse than healthy controls.

Lesh, Tyler A et al.·Schizophrenia bulletin open·2024·Moderate EvidenceObservational
RTHC-05468ObservationalModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Moderate Evidence
Sample
N=48

What This Study Found

First-episode schizophrenia patients with cannabis history (FES+CAN, n=48) showed higher cognitive control performance and higher dorsolateral prefrontal cortex (DLPFC) activation during task-based fMRI compared to patients without cannabis history (FES-CAN, n=28). FES+CAN and healthy controls (n=59) had similar DLPFC activation levels. However, younger cannabis initiation age was associated with lower IQ and functioning.

Key Numbers

48 FES+CAN; 28 FES-CAN; 59 controls; FES+CAN showed higher cognitive control (d-context) than FES-CAN (p < .05); FES+CAN and CON had similar DLPFC activation; earlier cannabis onset linked to lower IQ; more frequent use linked to higher reality distortion

How They Did This

Cross-sectional fMRI study of 48 first-episode schizophrenia patients with cannabis history, 28 without, and 59 healthy controls performing the AX-Continuous Performance Task measuring cognitive control.

Why This Research Matters

The paradox of better cognitive function in cannabis-using schizophrenia patients has been replicated across studies. This fMRI evidence adds a neural basis, suggesting these patients may have better-preserved prefrontal function.

The Bigger Picture

One explanation is that cannabis use in schizophrenia may select for individuals with better premorbid cognitive functioning. This does not mean cannabis is protective, as earlier initiation and heavier use still predicted worse outcomes.

What This Study Doesn't Tell Us

Cross-sectional design cannot determine causality or direction of association; selection bias (better-functioning patients may be more likely to access and use cannabis); cannot assess premorbid cognitive function; cannabis history based on self-report; relatively small groups

Questions This Raises

  • ?Does cannabis use in schizophrenia reflect a selection effect (higher-functioning patients use cannabis) or does cannabis exposure somehow preserve prefrontal function?
  • ?Would longitudinal data clarify this paradox?

Trust & Context

Key Stat:
48 cannabis-using vs 28 non-using schizophrenia patients compared by fMRI
Evidence Grade:
Well-designed neuroimaging study with appropriate controls, but cross-sectional design cannot resolve the selection vs. causation question.
Study Age:
2024 study
Original Title:
Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia.
Published In:
Schizophrenia bulletin open, 5(1), sgae016 (2024)
Database ID:
RTHC-05468

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Why do schizophrenia patients who use cannabis perform better cognitively?

This is a well-replicated paradox. One likely explanation is selection bias: individuals with better premorbid cognitive functioning and brain health may be more likely to seek out and obtain cannabis. The fMRI data showed their prefrontal cortex was more active during cognitive tasks, similar to healthy controls.

Does this mean cannabis helps schizophrenia?

No. While cannabis-using patients showed better cognitive performance, younger cannabis initiation age was associated with lower IQ and worse global functioning, and more frequent use correlated with more psychotic symptoms. The cognitive advantage likely reflects who uses cannabis rather than a benefit of cannabis itself.

Read More on RethinkTHC

Cite This Study

RTHC-05468·https://rethinkthc.com/research/RTHC-05468

APA

Lesh, Tyler A; Rhilinger, Joshua; Brower, Rylee; Mawla, Alex M; Ragland, J Daniel; Niendam, Tara A; Carter, Cameron S. (2024). Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia.. Schizophrenia bulletin open, 5(1), sgae016. https://doi.org/10.1093/schizbullopen/sgae016

MLA

Lesh, Tyler A, et al. "Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals With First-Episode Schizophrenia.." Schizophrenia bulletin open, 2024. https://doi.org/10.1093/schizbullopen/sgae016

RethinkTHC

RethinkTHC Research Database. "Using Task-fMRI to Explore the Relationship Between Lifetime..." RTHC-05468. Retrieved from https://rethinkthc.com/research/lesh-2024-using-taskfmri-to-explore

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.